Alitretinoin Suppliers & Bulk Manufacturers
Available Forms: Capsule / Gel
Available Strengths: 10 mg, 30 mg, 0.1%
Reference Brands: Panretin (USA), Toctino (EU)
Category:
Derma Drugs
Alitretinoin is available in Capsule / Gel
and strengths such as 10 mg, 30 mg, 0.1%.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Alitretinoin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Alitretinoin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Alitretinoin, also known as 9-cis-retinoic acid, is a naturally occurring derivative of vitamin A and a first-generation retinoid with both oral and topical therapeutic activity. It was developed by Ligand Pharmaceuticals and received regulatory approval in 1999 for medical use. Alitretinoin exhibits antineoplastic and chemopreventive properties and has been used in the management of specific dermatological and oncological conditions.
At the molecular level, alitretinoin binds to and activates both retinoic acid receptors (RAR) and retinoid X receptors (RXR), which function as nuclear transcription factors. Activation of these receptors leads to modulation of gene expression involved in cell growth and differentiation. Through this mechanism, alitretinoin inhibits abnormal cell proliferation, promotes cellular differentiation, and induces apoptosis in both normal and malignant cells.
Alitretinoin is administered orally or topically depending on the indication. Its pharmacological profile supports its use in severe dermatological disorders and selected cancer-related conditions where regulation of cell growth and immune response is required. Due to its retinoid nature, alitretinoin also carries known teratogenic and embryotoxic risks, necessitating careful patient selection and monitoring during therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing